Optimizing intravenous amoxicillin for outpatient parenteral antimicrobial therapy
JAC-Antimicrobial Resistance · 02.07.2026 · 8 (4)
DOI: 10.1093/jacamr/dlag165 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAC-Antimicrobial Resistance, online erschienen am 06.08.2026. Verfasst von Zenaw T Wolie und 6 weiteren Autor:innen. Beteiligte Einrichtung: Frazer Institute, Faculty of Health, Medicine and Behavioural Sciences, The University of Queensland, Brisbane, Queensland, Australia. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: BSAC OPAT.
Abstract (Originalsprache)
Background and objectives Poor aqueous stability limits the use of continuous infusion of intravenous (IV) amoxicillin in outpatient parenteral antimicrobial therapy. This study aimed to evaluate whether buffering improves amoxicillin stability and whether co-administration of probenecid enhances amoxicillin exposure.
Methods
Amoxicillin solutions (4.17, 50, and 66.6 mg/mL) were prepared in 0.3% citrate-buffered saline (pH 7), water for injection, and 0.9% w/v saline, then stored at 2–8°C for 10 days, followed by 24 h at 32°C. Stability was assessed using a validated assay method and tested against the UK Yellow Cover Document (YCD) acceptance criteria. A population pharmacokinetic model was developed and used to perform Monte Carlo dosing simulations to evaluate the PTA (95% time above MIC) for various IV amoxicillin regimens, with and without probenecid.
Results
Citrate buffering did not improve the stability of amoxicillin, and none of the tested conditions met YCD criteria. Co-administration of probenecid significantly increased the PTA for amoxicillin. Administration of 3–6 g of IV amoxicillin every 12 h, with 1 g of probenecid once daily, achieved ≥90% PTA against pathogens with MICs up to 4–8 mg/L depending on infusion durations. For MICs up to 16 mg/L, 4–6 g of IV amoxicillin every 12 h plus 2 g of probenecid once daily achieved a favourable PTA (>90%).
Conclusions
Amoxicillin’s aqueous instability was not resolved by citrate buffering. However, for patients requiring IV therapy, probenecid-boosted intermittent and extended infusion regimens of amoxicillin appear to be promising alternatives that warrant further clinical investigation.
Autor:innen und Institutionen
- Frazer Institute, Faculty of Health, Medicine and Behavioural Sciences, The University of Queensland, Brisbane, Queensland, Australia.
- Department of Pharmacy, College of Medicine and Health Sciences, Debre Markos University, Debre Markos, Ethiopia.
- Herston Infectious Diseases Institute (HeIDI), Metro North Health, Brisbane, Queensland, Australia.
- Departments of Pharmacy and Intensive Care Medicine, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia.
- UR UM 103, University of Montpellier, Division of Anesthesia Critical Care and Emergency and Pain Medicine, Nimes University Hospital, Nimes, France.
- Department of Pharmacy, College of Medicine and Health Sciences, Wollo University, Dessie, Ethiopia.
ORCID-Profile: Steven C Wallis, Mark Gilchrist, Fekade B Sime
Förderung
- BSAC OPAT
Zitieren
APA
Wolie, Z. T., Roberts, J. A., Wallis, S. C., Assefa, G. M., Seaton, R. A., Gilchrist, M., & Sime, F. B. (2026). Optimizing intravenous amoxicillin for outpatient parenteral antimicrobial therapy. JAC-Antimicrobial Resistance, 8(4). https://doi.org/10.1093/jacamr/dlag165
Vancouver
Wolie ZT, Roberts JA, Wallis SC, Assefa GM, Seaton RA, Gilchrist M, et al. Optimizing intravenous amoxicillin for outpatient parenteral antimicrobial therapy. JAC-Antimicrobial Resistance. 2026;8(4). doi:10.1093/jacamr/dlag165
BibTeX
@article{Wolie2026,
author = {Wolie, Zenaw T and Roberts, Jason A and Wallis, Steven C and Assefa, Getnet M and Seaton, R Andrew and Gilchrist, Mark and Sime, Fekade B},
title = {Optimizing intravenous amoxicillin for outpatient parenteral antimicrobial therapy},
journal = {JAC-Antimicrobial Resistance},
year = {2026},
volume = {8},
number = {4},
doi = {10.1093/jacamr/dlag165}
}
EUVIMED